Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0P3FZ
|
||||
Former ID |
DNC012930
|
||||
Drug Name |
5-(piperidin-4-yl)isothiazol-3-ol
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C8H12N2OS
|
||||
Canonical SMILES |
C1CNCCC1C2=CC(=O)NS2
|
||||
InChI |
1S/C8H12N2OS/c11-8-5-7(12-10-8)6-1-3-9-4-2-6/h5-6,9H,1-4H2,(H,10,11)
|
||||
InChIKey |
WUINUICOEAZPLK-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Gamma-aminobutyric acid receptor | Target Info | Inhibitor | [1] | |
Gamma-aminobutyric acid receptor subunit gamma-2 | Target Info | Inhibitor | [1] | ||
Gamma-aminobutyric acid receptor subunit alpha-1 | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Retrograde endocannabinoid signaling | |||||
GABAergic synapse | |||||
Morphine addiction | |||||
Nicotine addictionhsa04080:Neuroactive ligand-receptor interaction | |||||
Nicotine addiction | |||||
Reactome | Ligand-gated ion channel transport | ||||
GABA A receptor activationR-HSA-975298:Ligand-gated ion channel transport | |||||
GABA A receptor activation | |||||
WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
Iron uptake and transportWP706:SIDS Susceptibility Pathways | |||||
Iron uptake and transport | |||||
References | |||||
REF 1 | J Med Chem. 2006 Feb 23;49(4):1388-96.Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.